Skip to main content

Table 3 Linear regression models of estimated 30 days percent reduction in anti-RBD level

From: The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

 

Model 1

β (95% CI)

Model 2

β (95% CI)

Model 3

β (95% CI)

Model 4

β (95% CI)

Demographics

 Age in years

0.0 (-0.0–0.1)

0.1 (-0.0–0.1)

-0.0 (-0.1–0.0)

-0.0 (-0.1–0.0)

 Female gender

1.2 (-0.1–2.4)

1.2 (-0.1–2.4)

0.7 (-0.6–1.9)

0.7 (-0.6–2.1)

 Patients vs controls

-6.4 (-8.4–-4.3) **

-4.9 (-7.4–-2.4)*

-

 

Vaccine type

 BNT162b2 x 2

 

-

  

 COVID-19 infection and vaccine

 

8.3 (-0.2–16.8)

  

 Mixeda

 

2.8 (0.2–5.4)*

  

 mRNA-1273 x 2

 

4.4 (3.0–5.9) **

  

Medication

 Methotrexate monotherapy

  

-1.9 (-4.3– 0.5)

-

 Interleukin inhibitors

  

-0.9 (-4.5–2.7)

1.8 (-1.7–5.3)

 Vedolizumab

  

0.7 (-3.3–4.7)

5.1 (0.7–9.5)*

 TNF mono

  

-8.6 (-10.7–-6.5) **

-6.2 (-8.4–-4.1)**

 TNF comb

  

-8.1 (-10.4–-5.9)**

-6.0 (-8.0–-4.0)**

 Rituximab

  

-0.3 (-4.8–4.2)

1.0 (-3.3–5.3)

Diagnosis

 Rheumatoid arthritis

   

-

 Psoriatic arthritis

   

0.5 (-1.4–2.5)

 Spondyloarthritis

   

0.8 (-1.4–3.1)

 Ulcerative colitis

   

-2.9 (-5.7–-0.2)*

 Crohn’s disease

   

-2.3 (-4.7–0.1)

R2adjusted

0.21

0.23

0.26

0.26

  1. Linear regression models. Dependent variable of each model is estimated reduction in anti-RBD level in 30 days
  2. All models are adjusted for anti-RBD levels at first assessment and time between first and second sera assessment. Please see Table S1 for details
  3. Variables selected by forwards stepwise selection
  4. Model 1 includes age, sex and patients vs. controls
  5. Model 2 includes age, sex, patients vs. controls and type of vaccine
  6. Model 3 includes age, sex, type immunosuppressive medication vs controls
  7. Model 4 includes age, sex, type immunosuppressive medication and diagnosis. Controls were excluded from this model due to collinearity. (Methotrexate monotherapy and rheumatoid arthritis are comparators)
  8. *p < 0.05, **p < 0.001
  9. aChAdOx1 + BNT162b2/mRNA-1273 or BNT162b2 + mRNA-1273